Roche’s Itovebi joined the party late last year. Lilly’s attempt to follow its peers took a hit last year when it axed LOXO-783 after comparing clinical data on the molecule to its next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback